IL17A and inflammatory bowel disease: Therefore, the possibility that these patients may develop IBD or that they already have clinically silent gut inflammation should raise caution with rheumatologists when choosing a biologic drug given the tissue-specific roles of IL-17, which are probably detrimental in the joints and protective in the gut.